Calcitonin gene-related peptide receptor antagonists for migraine

Expert Opinion on Investigational Drugs

Volumn 19, Issue 7, 2010, Pages 815-823

  Fischer, Michael J ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Headache; Meningeal nociception; Migraine; Neuropeptide; Pain

Indexed keywords

ALPHA CALCITONIN GENE RELATED PEPTIDE; BETA CALCITONIN GENE RELATED PEPTIDE; BI 44370; BMS 694153; CALCITONIN GENE RELATED PEPTIDE; CALCITONIN GENE RELATED PEPTIDE RECEPTOR; CALCITONIN GENE RELATED PEPTIDE RECEPTOR ANTAGONIST; CALCITONIN GENE RELATED PEPTIDE[8-37]; IBUPROFEN; MK 3207; NOX C 89; OLCEGEPANT; PARACETAMOL; PLACEBO; QUININE DERIVATIVE; RIZATRIPTAN; SB 273779; SUMATRIPTAN; TELCAGEPANT; UNCLASSIFIED DRUG; VANILLOID RECEPTOR 1; ZOLMITRIPTAN;

CLINICAL TRIAL; CLUSTER HEADACHE; COMBINATION CHEMOTHERAPY; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG HALF LIFE; DRUG PENETRATION; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG TARGETING; DRUG UPTAKE; HORMONE RELEASE; HUMAN; IC 50; MIGRAINE; MONOTHERAPY; NONHUMAN; PATHOPHYSIOLOGY; PROTEIN EXPRESSION; REVIEW; SIDE EFFECT; TRIGEMINAL NERVE; TRIGEMINUS NEURALGIA; UNSPECIFIED SIDE EFFECT;

ANIMALS; AZEPINES; CALCITONIN GENE-RELATED PEPTIDE; CLINICAL TRIALS AS TOPIC; DIPEPTIDES; HUMANS; IMIDAZOLES; INDAZOLES; MIGRAINE DISORDERS; QUINAZOLINES; QUINAZOLINONES; RECEPTORS, CALCITONIN GENE-RELATED PEPTIDE; TREATMENT OUTCOME; TRIGEMINAL NERVE;

EID: 77953451982     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.2010.490829     Document Type: Review

References (100)

1. Cerbo R, Pesare M, Aurilia C, et al. Socio-economic costs of migraine. J Headache Pain 2004;2:s15-19
2. Amara SG, Jonas V, Rosenfeld MG, et al. Alternative RNA processing in calcitonin gene expression generates mRNAs encoding different polypeptide products. Nature 1982;298:240-244
3. Wimalawansa SJ. Calcitonin gene-related peptide and its receptors: molecular genetics, physiology, pathophysiology, and therapeutic potentials. Endocr Rev 1996;17:533-585
4. Hanko J, Hardebo JE, Kahrstrom J, et al. Calcitonin gene-related peptide is present in mammalian cerebrovascular nerve fibres and dilates pial and peripheral arteries. Neurosci Lett 1985;57:91-95
5. Vega AV, Avila G. CGRP, a vasodilator neuropeptide that stimulates neuromuscular transmission and EC coupling. Curr Vasc Pharmacol 2010;8:394-403
6. Lu JT, Son YJ, Lee J, et al. Mice lacking alpha-calcitonin gene-related peptide exhibit normal cardiovascular regulation and neuromuscular development. Mol Cell Neurosci 1999;14:99-120
7. Kraenzlin ME, Ch'ng JL, Mulderry PK, et al. Infusion of a novel peptide, calcitonin gene-related peptide (CGRP) in man. Pharmacokinetics and effects on gastric acid secretion and on gastrointestinal hormones. Regul Pept 1985;10:189-197
8. Aiyar N, Rand K, Elshourbagy NA, et al. A cDNA encoding the calcitonin gene-related peptide type 1 receptor. J Biol Chem 1996;271:11325-11329
9. McLatchie LM, Fraser NJ, Main MJ, et al. RAMPs regulate the transport and ligand specificity of the calcitonin-receptor-like receptor. Nature 1998;393:333-339
10. Ma W, Chabot JG, Powell KJ, et al. Localization and modulation of calcitonin gene-related peptide-receptor component protein-immunoreactive cells in the rat central and peripheral nervous systems. Neuroscience 2003;120:677-694
11. Sams A, Jansen-Olesen I. Expression of calcitonin receptor-like receptor and receptor-activity-modifying proteins in human cranial arteries. Neurosci Lett 1998;258:41-44
12. Koth CM, Abdul-Manan N, Lepre CA, et al. Refolding and characterization of a soluble ectodomain complex of the calcitonin gene-related peptide receptor. Biochemistry 2010;49:1862-1872
13. Barwell J, Miller PS, Donnelly D, Poyner DR. Mapping interaction sites within the N-terminus of the calcitonin gene-related peptide receptor; the role of residues 23-60 of the calcitonin receptor-like receptor. Peptides 2010;31:170-176
14. Hay DL, Poyner DR, Smith DM. Desensitisation of adrenomedullin and CGRP receptors. Regul Pept 2003;112:139-145
15. Feindel W, Penfield W, McNaughton FL. The tentorial nerves and localization of intracranial pain in man. Neurology 1960;10:555-563
16. Penfield W. A contribution to the mechanism of intracranial pain. Proc Assoc Res Nerv Mental Dis 1934;15:399-415
17. Ray BS, Wolff HG. Experimental studies on headache: pain-sensitive structures of the head and their significance in headache. Arch Surg 1940;41:813-856
18. Tajti J, Uddman R, Moller S, et al. Messenger molecules and receptor mRNA in the human trigeminal ganglion. J Auton Nerv Syst 1999;76:176-183
19. Skofitsch G, Jacobowitz DM. Calcitonin gene-related peptide coexists with substance P in capsaicin sensitive neurons and sensory ganglia of the rat. Peptides 1985;6:747-754
20. Lee Y, Kawai Y, Shiosaka S, et al. Coexistence of calcitonin gene-related peptide and substance P-like peptide in single cells of the trigeminal ganglion of the rat: immunohistochemical analysis. Brain Res 1985;330:194-196
21. Messlinger K, Hanesch U, Baumgartel M, et al. Innervation of the dura mater encephali of cat and rat: ultrastructure and calcitonin gene-related peptide-like and substance P-like immunoreactivity. Anat Embryol (Berl) 1993;188:219-237
22. Liu Y, Broman J, Edvinsson L. Central projections of the sensory innervation of the rat middle meningeal artery. Brain Res 2008;1208:103-110
23. Mason RT, Peterfreund RA, Sawchenko PE, et al. Release of the predicted calcitonin gene-related peptide from cultured rat trigeminal ganglion cells. Nature 1984;308:653-655
24. Eberhardt M, Hoffmann T, Sauer SK, et al. Calcitonin gene-related peptide release from intact isolated dorsal root and trigeminal ganglia. Neuropeptides 2008;42:311-317
25. Jenkins DW, Langmead CJ, Parsons AA, Strijbos PJ. Regulation of calcitonin gene-related peptide release from rat trigeminal nucleus caudalis slices in vitro. Neurosci Lett 2004;366:241-244
26. Ebersberger A, Averbeck B, Messlinger K, Reeh PW. Release of substance P, calcitonin gene-related peptide and prostaglandin E2 from rat dura mater encephali following electrical and chemical stimulation in vitro. Neuroscience 1999;89:901-907 (Pubitemid 29071014)
27. Strecker T, Dux M, Messlinger K. Nitric oxide releases calcitonin-gene-related peptide from rat dura mater encephali promoting increases in meningeal blood flow. J Vasc Res 2002;39:489-496
28. Zimmermann K, Reeh PW, Averbeck B. ATP can enhance the proton-induced CGRP release through P2Y receptors and secondary PGE(2) release in isolated rat dura mater. Pain 2002;97:259-265
29. Fischer MJ, Messlinger K. Cannabinoid and vanilloid effects of R (+)-methanandamide in the hemisected meningeal preparation. Cephalalgia 2007;27:422-428
30. Goadsby PJ, Edvinsson L, Ekman R. Release of vasoactive peptides in the extracerebral circulation of humans and the cat during activation of the trigeminovascular system. Ann Neurol 1988;23:193-196
31. Tfelt-Hansen P, Le H. Calcitonin gene-related peptide in blood: is it increased in the external jugular vein during migraine and cluster headache? A review. J Headache Pain 2009;10:137-143
32. Jansen-Olesen I, Mortensen A, Edvinsson L. Calcitonin gene-related peptide is released from capsaicin-sensitive nerve fibres and induces vasodilatation of human cerebral arteries concomitant with activation of adenylyl cyclase. Cephalalgia 1996;16:310-316
33. Juhasz G, Zsombok T, Modos EA, et al. NO-induced migraine attack: strong increase in plasma calcitonin gene-related peptide (CGRP) concentration and negative correlation with platelet serotonin release. Pain 2003;106:461-470
34. Eberhardt M, Neeb L, Vogel EM, et al. Glyceroltrinitrate facilitates stimulated CGRP release but not gene expression of CGRP or its receptor components in rat trigeminal ganglia. Neuropeptides 2009;43:483-489
35. Price TJ, Flores CM. Critical evaluation of the colocalization between calcitonin gene-related peptide, substance P, transient receptor potential vanilloid subfamily type 1 immunoreactivities, and isolectin B4 binding in primary afferent neurons of the rat and mouse. J Pain 2007;8:263-272
36. Fusco BM, Fiore G, Gallo F, et al. 'Capsaicin-sensitive' sensory neurons in cluster headache: pathophysiological aspects and therapeutic indication. Headache 1994;34:132-137
37. Petersen KA, Birk S, Doods H, et al. Inhibitory effect of BIBN4096BS on cephalic vasodilatation induced by CGRP or transcranial electrical stimulation in the rat. Br J Pharmacol 2004;143:697-704
38. Bolay H, Reuter U, Dunn AK, et al. Intrinsic brain activity triggers trigeminal meningeal afferents in a migraine model. Nat Med 2002;8:136-142
39. Le Greves P, Nyberg F, Terenius L, Hokfelt T. Calcitonin gene-related peptide is a potent inhibitor of substance P degradation. Eur J Pharmacol 1985;115:309-311
40. Oku R, Satoh M, Fujii N, et al. Calcitonin gene-related peptide promotes mechanical nociception by potentiating release of substance P from the spinal dorsal horn in rats. Brain Res 1987;403:350-354
41. Mao J, Coghill RC, Kellstein DE, et al. Calcitonin gene-related peptide enhances substance P-induced behaviors via metabolic inhibition: in vivo evidence for a new mechanism of neuromodulation. Brain Res 1992;574:157-163
42. Storer RJ, Akerman S, Goadsby PJ. Calcitonin gene-related peptide (CGRP) modulates nociceptive trigeminovascular transmission in the cat. Br J Pharmacol 2004;142:1171-1181
43. Kangrga I, Randic M. Tachykinins and calcitonin gene-related peptide enhance release of endogenous glutamate and aspartate from the rat spinal dorsal horn slice. J Neurosci 1990;10:2026-2038
44. Shekhar YC, Anand IS, Sarma R, et al. Effects of prolonged infusion of human alpha calcitonin gene-related peptide on hemodynamics, renal blood flow and hormone levels in congestive heart failure. Am J Cardiol 1991;67:732-736
45. Lassen LH, Haderslev PA, Jacobsen VB, et al. CGRP may play a causative role in migraine. Cephalalgia 2002;22:54-61
46. Recober A, Kuburas A, Zhang Z, et al. Role of calcitonin gene-related peptide in light-aversive behavior: implications for migraine. J Neurosci 2009;29:8798-8804
47. Chiba T, Yamaguchi A, Yamatani T, et al. Calcitonin gene-related peptide receptor antagonist human CGRP-(8-37). Am J Physiol 1989;256:E331-3
48. Carpenter KA, Schmidt R, von Mentzer B, et al. Turn structures in CGRP C-terminal analogues promote stable arrangements of key residue side chains. Biochemistry 2001;40:8317-8325
49. Vanmolkot FH, Van der Schueren BJ, de Hoon JN. Calcitonin gene-related peptide-induced vasodilation in the human forearm is antagonized by CGRP8-37: evaluation of a human in vivo pharmacodynamic model. Clin Pharmacol Ther 2006;79:263-273
50. Miranda LP, Holder JR, Shi L, et al. Identification of potent, selective, and metabolically stable peptide antagonists to the calcitonin gene-related peptide (CGRP) receptor. J Med Chem 2008;51:7889-7897
51. Daines RA, Sham KKC, Taggert JJ, et al. Quinine analogs as non-peptide calcitonin gene-related peptide (CGRP) receptor antagonists. Bioorg Med Chem Lett 1997;7:2673-2676
52. Doods H, Hallermayer G, Wu D, et al. Pharmacological profile of BIBN4096BS, the first selective small molecule CGRP antagonist. Br J Pharmacol 2000;129:420-423
53. Aiyar N, Daines RA, Disa J, et al. Pharmacology of SB-273779, a nonpeptide calcitonin gene-related peptide 1 receptor antagonist. J Pharmacol Exp Ther 2001;296:768-775
54. Nichols PL, Brand J, Briggs M, et al. Potent oxadiazole CGRP receptor antagonists for the potential treatment of migraine. Bioorg Med Chem Lett 2010;20:1368-1372
55. Mallee JJ, Salvatore CA, LeBourdelles B, et al. Receptor activity-modifying protein 1 determines the species selectivity of non-peptide CGRP receptor antagonists. J Biol Chem 2002;277:14294-14298
56. Hasbak P, Saetrum OO, Eskesen K, et al. Investigation of CGRP receptors and peptide pharmacology in human coronary arteries. Characterization with a nonpeptide antagonist. J Pharmacol Exp Ther 2003;304:326-333
57. Vater A, Jarosch F, Buchner K, Klussmann S. Short bioactive Spiegelmers to migraine-associated calcitonin gene-related peptide rapidly identified by a novel approach: tailored-SELEX. Nucleic Acids Res 2003;31:e130
58. Denekas T, Troltzsch M, Vater A, et al. Inhibition of stimulated meningeal blood flow by a calcitonin gene-related peptide binding mirror-image RNA oligonucleotide. Br J Pharmacol 2006;148:536-543
59. Juhl L, Edvinsson L, Olesen J, Jansen-Olesen I. Effect of two novel CGRP-binding compounds in a closed cranial window rat model. Eur J Pharmacol 2007;567:117-124
60. Paone DV, Shaw AW, Nguyen DN, et al. Potent, orally bioavailable calcitonin gene-related peptide receptor antagonists for the treatment of migraine: discovery of N-[(3R,6S)-6-(2,3-difluorophenyl)-2-oxo-1-(2,2,2- trifluoroethyl)azepan-3-yl]-4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl) piperidine-1-carboxamide (MK-0974). J Med Chem 2007;50:5564-5567
61. Salvatore CA, Hershey JC, Corcoran HA, et al. Pharmacological characterization of MK-0974 [N-[(3R,6S)-6-(2,3-difluorophenyl)-2-oxo-1-(2,2,2- trifluoroethyl)azepan-3-yl]-4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl) piperidine-1-carboxamide], a potent and orally active calcitonin gene-related peptide receptor antagonist for the treatment of migraine. J Pharmacol Exp Ther 2008;324:416-421
62. Bell IM, Bednar RA, Corcoran HA, et al. The identification of potent, orally bioavailable tricyclic CGRP receptor antagonists. Bioorg Med Chem Lett 2009;19:4740-4742
63. Wood MR, Schirripa KM, Kim JJ, et al. Novel CGRP receptor antagonists through a design strategy of target simplification with addition of molecular flexibility. Bioorg Med Chem Lett 2009;19:5787-5790
64. Stump CA, Bell IM, Bednar RA, et al. The discovery of highly potent CGRP receptor antagonists. Bioorg Med Chem Lett 2009;19:214-217
65. Bell IM, Galliccio SN, Wood MR, et al. Discovery of MK-3207: a highly potent, orally bioavailable CGRP receptor antagonist. ACS Med Chem Lett 2010;1:24-29
66. Salvatore CA, Moore EL, Calamari A, et al. Pharmacological properties of MK-3207 [2-[(8R)-8-(3,-difluorophenyl)-10-oxo-6,9-diazaspiro[4.5]dec-9-yl]-N- [(2R)-2'-ox o-1,1',2',3-tetrahydrospiro [indene-2,3'-pyrrolo[2,3-b]pyridin]-5- yl] acetamide], a potent and orally active CGRP receptor antagonist. J Pharmacol Exp Ther 2010;333:152-160
67. Degnan AP, Chaturvedula PV, Conway CM, et al. Discovery of (R)-4-(8-fluoro-2-oxo-1,2-dihydroquinazolin-3 (4H)-yl)-N-(3-(7-methyl-1H- indazol-5-yl)-1-oxo-1-(4-(piperidin-1-yl)piperidin-1-yl)propan-2-yl) piperidine-1-carboxami de (BMS-694153): a potent antagonist of the human calcitonin gene-related peptide receptor for migraine with rapid and efficient intranasal exposure. J Med Chem 2008;51:4858-4861
68. Peterlin BL, Rapoport AM. Clinical pharmacology of the serotonin receptor agonist, zolmitriptan. Expert Opin Drug Metab Toxicol 2007;3:899-911
69. Diener HC, Evers S. Effectiveness and satisfaction with zolmitriptan 5 mg nasal spray for treatment of migraine in real-life practice: results of a postmarketing surveillance study. Clin Drug Investig 2007;27:59-66
70. Degnan AP, Conway CM, Dalterio RA, et al. Carbamates as potent calcitonin gene-related peptide antagonists with improved solution stability. Bioorg Med Chem Lett 2009;19:3555-3558
71. Leniger T, Pageler L, Stude P, et al. Comparison of intravenous valproate with intravenous lysine-acetylsalicylic acid in acute migraine attacks. Headache 2005;45:42-46
72. Williamson DJ, Hargreaves RJ. Neurogenic inflammation in the context of migraine. Microsc Res Tech 2001;53:167-178
73. Fischer MJ, Koulchitsky S, Messlinger K. The nonpeptide calcitonin gene-related peptide receptor antagonist BIBN4096BS lowers the activity of neurons with meningeal input in the rat spinal trigeminal nucleus. J Neurosci 2005;25:5877-5883
74. Koulchitsky S, Fischer MJ, Messlinger K. Calcitonin gene-related peptide receptor inhibition reduces neuronal activity induced by prolonged increase in nitric oxide in the rat spinal trigeminal nucleus. Cephalalgia 2009;29:408-417
75. Edvinsson L. CGRP blockers in migraine therapy: where do they act? Br J Pharmacol 2008;155:967-969
76. Levy D, Burstein R, Strassman AM. Calcitonin gene-related peptide does not excite or sensitize meningeal nociceptors: implications for the pathophysiology of migraine. Ann Neurol 2005;58:698-705
77. Sixt ML, Messlinger K, Fischer MJ. Calcitonin gene-related peptide receptor antagonist olcegepant acts in the spinal trigeminal nucleus. Brain 2009;132:3134-3141
78. Sur C, Hargreaves R, Bell I, et al. CSF levels and binding pattern of novel CGRP receptor antagonists in rhesus monkey and human central nervous system: toward the development of a PET tracer. Cephalagia 2009;29:136-137
79. Moore EL, Gingell JJ, Kane SA, et al. Mapping the CGRP receptor ligand binding domain. tryptophan-84 of RAMP1 is critical for agonist and antagonist binding. Biochem Biophys Res Commun 2010;394:141-145
80. Miller PS, Barwell J, Poyner DR, et al. Non-peptidic antagonists of the CGRP receptor, BIBN4096BS and MK-0974, interact with the calcitonin receptor-like receptor via methionine-42 and RAMP1 via tryptophan-74. Biochem Biophys Res Commun 2010;391:437-442
81. Poyner DR, Hay DL, Connor AC. CGRP receptor antagonists: design and screening. Exp Opin Drug Discov 2009;4:1253-1265
82. Iovino M, Feifel U, Yong CL, et al. Safety, tolerability and pharmacokinetics of BIBN 4096 BS, the first selective small molecule calcitonin gene-related peptide receptor antagonist, following single intravenous administration in healthy volunteers. Cephalalgia 2004;24:645-656
83. Petersen KA, Birk S, Lassen LH, et al. The CGRP-antagonist, BIBN4096BS does not affect cerebral or systemic haemodynamics in healthy volunteers. Cephalalgia 2005;25:139-147
84. Van der Schueren BJ, Rogiers A, Vanmolkot FH, et al. Calcitonin gene-related peptide8-37 antagonizes capsaicin-induced vasodilation in the skin: evaluation of a human in vivo pharmacodynamic model. J Pharmacol Exp Ther 2008;325:248-255
85. Sinclair SR, Kane SA, Van der Schueren BJ, et al. Inhibition of capsaicin-induced increase in dermal blood flow by the oral CGRP receptor antagonist, telcagepant (MK-0974). Br J Clin Pharmacol 2010;69:15-22
86. Petersen KA, Lassen LH, Birk S, et al. BIBN4096BS antagonizes human alpha-calcitonin gene related peptide-induced headache and extracerebral artery dilatation. Clin Pharmacol Ther 2005;77:202-213
87. Olesen J, Diener HC, Husstedt IW, et al. Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. N Engl J Med 2004;350:1104-1110
88. Ho TW, Mannix LK, Fan X, et al. Randomized controlled trial of an oral CGRP receptor antagonist, MK-0974, in acute treatment of migraine. Neurology 2008;70:1304-1312
89. Ho TW, Ferrari MD, Dodick DW, et al. Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trial. Lancet 2008;372:2115-2123
90. Connor KM, Shapiro RE, Diener HC, et al. Randomized, controlled trial of telcagepant for the acute treatment of migraine. Neurology 2009;73:970-977
91. Han TH, Blanchard RL, Palcza J, et al. Single-and multiple-dose pharmacokinetics and tolerability of telcagepant, an oral calcitonin gene\related peptide receptor antagonist, in adults. J Clin Pharmacol 2010. [Epub ahead of print]
92. Roller S, Cui D, Laspina C, et al. Preclinical pharmacokinetics of MK-0974, an orally active calcitonin-gene related peptide (CGRP)-receptor antagonist, mechanism of dose dependency and species differences. Xenobiotica 2009;39:33-45
93. Kroeger I, Erhardt A, Abt D, et al. The neuropeptide calcitonin gene-related peptide (CGRP) prevents inflammatory liver injury in mice. J Hepatol 2009;51:342-353
94. Dodick D, Lipton RB, Martin V, et al. Consensus statement: cardiovascular safety profile of triptans (5-HT agonists) in the acute treatment of migraine. Headache 2004;44:414-425
95. Regan CP, Stump GL, Kane SA, Lynch JJ Jr. Calcitonin gene-related peptide receptor antagonism does not affect the severity of myocardial ischemia during atrial pacing in dogs with coronary artery stenosis. J Pharmacol Exp Ther 2009;328:571-578
96. Edvinsson L, Alm R, Shaw D, et al. Effect of the CGRP receptor antagonist BIBN4096BS in human cerebral, coronary and omental arteries and in SK-N-MC cells. Eur J Pharmacol 2002;434:49-53
97. Lynch JJ Jr, Regan CP, Md LE, et al. Comparison of the vasoconstrictor effects of the calcitonin gene-related peptide (CGRP) receptor antagonist telcagepant (MK-0974) and zolmitriptan in human isolated coronary arteries. J Cardiovasc Pharmacol 2010. [Epub ahead of print]
98. Hou JF, Yu LC. Blockade effects of BIBN4096BS on CGRP-induced inhibition on whole-cell K+ currents in spinal dorsal horn neuron of rats. Neurosci Lett 2010;469:15-18
99. Ferrari MD, Roon KI, Lipton RB, Goadsby PJ. Oral triptans (serotonin 5-HT(1B/1D) agonists) in acute migraine treatment: a meta-analysis of 53 trials. Lancet 2001;358:1668-1675
100. Tfelt-Hansen PC. Is there an inherent limit to the efficacy of calcitonin gene-related peptide receptor antagonists in the acute treatment of migraine? A comment. J Headache Pain 2009;10:389-391